Investor Presentation Q2FY23

Multiple Levers to drive growth Revenue Mix 25% Q2FY23 1(a) 303%95% (Source: IQVIA-Moving Annual Total Turnover- MAT Sep 2022) 4% 5% Domestic, 83% 7% Export, 17% Domestic Sales 26% 6% 56% 9% 29% Export Sales 102% 34% ■ Anti-Infectives ■ Gl ■ VMN ■ Derma ■ Ophthal ■Cardiac ■Gynaec. ■ Respiratory ■ Antiviral ■ Others 58% -7% -50% 235 294 274 347 369 31 48 96 48 75 Q2FY19 Q2FY20 Q2FY21 Q2FY22 Q2FY23 Q2FY19 Q2FY20 Q2FY21 Q2FY22 Q2FY23 Val Cr YOY Sales Growth % Val Cr YOY Sales Growth % Sales & Marketing (Source: Internal Data). 3,615 Medical representatives across 10 divisions marketing 130+ brands FDC

View entire presentation